We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Corneal Prosthesis Offers New Hope for Those Blinded in Accidents

By HospiMedica International staff writers
Posted on 02 Jun 2010
A novel hydrophobic polymer material is being used to manufacture a synthetic eye prosthesis that could offer patients that cannot receive a donor cornea a further option for corneal transplantation.

Researchers at the Fraunhofer Institute for Applied Polymer Research (IAP; Potsdam-Golm, Germany) developed the eye prosthesis jointly with physicians and manufacturers participating in the European Union Artificial Cornea project. More...
The first stage involved a common hydrophobic polymer that is coated along its edge with a specific sequence of a growth factor (GF). The surrounding natural cells detect this GF, and are stimulated by it to propagate and populate the surface of the corneal margin. Thus, the cells of the surrounding tissue grow with the implant, and the artificial cornea attains stability. The polymer, which is commercially available, repels water, so it will not absorb tear-duct secretions that could cause it to swell. It also prohibits cell growth in the central region, so natural tissue will not cloud it over.

The chemical-biomimetic coated implant was then sent to Regensburg University Medical Center (Germany), and to the medical center at the Technical University of Munich (Germany), where they were tested in dissected pigs eyes and specialized cell cultures. Eventually, the artificial corneas were tested in-vivo in rabbits; the design was further refined, the optics were reduced, and the implant haptic enlarged in order to maintain a more stable construction. The total development time took three years. The artificial cornea went into production in 2009 by Miro (Siegen, Germany), and the first in-human implantations began during the first six months of 2010.

"The new artificial cornea adheres to eye cells without needing to be held in place by sutures - a major advantage over other artificial corneas, which can cause inflammation and infection,” said Joachim Storsberg, Ph.D., head of functional medical polymer research at the IAP.

Corneal transplantation is a surgical procedure in which a damaged or diseased cornea is replaced in its entirety (penetrating keratoplasty) or in part (lamellar keratoplasty). The donated corneal graft is removed from a recently deceased individual with no known diseases or other factors that may affect the viability of the donated tissue, or the health of the recipient. There is a constant shortage worldwide in available corneal donor grafts.

Related Links:

Fraunhofer Institute for Applied Polymer Research
Regensburg University Medical Center
Technical University of Munich
Miro



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.